Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RaySearch Laboratories ABCHIX:RAYBS 93 Cash Ratio is 0.78 as of Mar. 2026, which is 86% above its 10-year median of 0.42. GuruFocus rates CHIX:RAYBS with a GF Score™ of 93/100 and a GF Value™ of kr178.48 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 666 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 58.26% on this metric.
RaySearch Laboratories AB has a Cash Ratio of 0.78. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for RaySearch Laboratories AB's Cash Ratio or its related term are showing as below:
CHIX:RAYBs'
s Cash Ratio Range Over the Past 10 Years
Min: 0.17 Med: 0.42 Max: 0.78
Current: 0.78
During the past 13 years, RaySearch Laboratories AB's highest Cash Ratio was 0.78. The lowest was 0.17. And the median was 0.42.
CHIX:RAYBs's Cash Ratio is ranked better than 58.26% of 666
companies
in the Healthcare Providers & Services industry
Industry Median: 0.58
vs CHIX:RAYBs: 0.78
RaySearch Laboratories AB (CHIX:RAYBs) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
RaySearch Laboratories AB Cash Ratio Related Terms
RaySearch Laboratories AB Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:RAYBS vs VEEV, BTSG, HQY: Cash Ratio Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB Cash Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB (CHIX:RAYBS) has a Cash Ratio of 0.78 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on RaySearch Laboratories AB and its competitors. This is 86% above median its historical median of 0.42. Over the past decade, RaySearch Laboratories AB's Cash Ratio has ranged from 0.17 to 0.78. According to the industry distribution chart, RaySearch Laboratories AB ranks #278 out of 666 companies in the Healthcare Providers & Services industry, placing it in the top 41.7%.
Is RaySearch Laboratories AB's Cash Ratio too high?
RaySearch Laboratories AB's current Cash Ratio of 0.78 is 86% above median its 10-year median of 0.42. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 0.78. The Healthcare Providers & Services industry median Cash Ratio is 0.58. RaySearch Laboratories AB's value of 0.78 is 34.5% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #278 out of 666 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, RaySearch Laboratories AB has a GF Score™ of 93/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Cash Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #278 out of 666 companies for Cash Ratio. This puts RaySearch Laboratories AB in the upper half of its industry. The industry median Cash Ratio is 0.58. RaySearch Laboratories AB's value of 0.78 is 34.5% above this benchmark. Historically, RaySearch Laboratories AB's own Cash Ratio has ranged from 0.17 to 0.78 over the past decade. While the company's 10-year median is 0.42 vs. the industry median of 0.58, RaySearch Laboratories AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Healthcare Providers & Services company?
The median Cash Ratio among Healthcare Providers & Services companies is 0.58, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current Cash Ratio of 0.78 is 34.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current Cash Ratio is 0.78, which is 86% above median its own 10-year median of 0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (CHIX:RAYBS) is currently considered Significantly Overvalued. The stock's GF Value™ is kr178.48, compared to a current price of kr234.70 — trading 31.5% above its estimated fair value. The current Cash Ratio is 0.78, which is 86% above median its 10-year median of 0.42 and 34.5% above the Healthcare Providers & Services industry median of 0.58. RaySearch Laboratories AB's overall GF Score™ is 93/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For RaySearch Laboratories AB (CHIX:RAYBS), the current Cash Ratio is 0.78 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (CHIX:RAYBS) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of kr234.70 is trading 31.5% above its estimated GF Value™ of kr178.48.
GuruFocus considers RaySearch Laboratories AB to be Significantly Overvalued.
Key valuation signals for CHIX:RAYBS:
Cash Ratio: 0.78 (86% above median its 10-year median of 0.42)
GF Value™: kr178.48 vs. price of kr234.70 (31.5% above fair value)
Industry Position: 34.5% above the Healthcare Providers & Services median (#278 of 666)
No single metric tells the full story. See the CHIX:RAYBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
93GF Score
Get the complete analysis for CHIX:RAYBS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:RAYBS has been successfully added to your 
